Christopher RowlandWashington Post·29 May, 2026 11:51 PM5 mins to readEli Lilly's experimental drug retatrutide led to an average 28% weight loss in obese patients. Photo / Getty ImagesPharmaceutical company Eli Lilly this month unveiled startling new data that showed an experimental weight-loss drug caused people with obesity to shed, on average, 28% of their body weight - a substantial step up in potency from the existing crop of GLP-1 medicines.
But that breakthrough is prompting some doctors
